Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2015 Dec 21;4(12):e180. doi: 10.1038/oncsis.2015.37

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

Copyright © 2015 Macmillan Publishers Limited

Oncogenesis is an open-access journal published by Nature Publishing Group. This work is licensed under a Creative Commons Attribution 4.0 International License. The images or other third party material in this article are included in the article's Creative Commons license, unless indicated otherwise in the credit line; if the material is not included under the Creative Commons license, users will need to obtain permission from the license holder to reproduce the material. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/

PMC Copyright notice

Sublethal dose of ETO treatment disturbs cell cycle profile. (a) ETO treatment (10 μM, 72 h) disturbs the cell cycle profile. Quantification of different cell cycle stages in adrenocortical Y1 tumor cells in the presence or absence of ETO. (b and c) EdU incorporation and mitotic index are reduced in ETO-treated (10 μM, 24 h) adrenocortical H295 and Y1 tumor cell lines. Quantification of EdU incorporation (b) or mitotic index (c) in scramble control (CTL) or ETO-treated H295 and Y1 cell lines. These results are mean +/−s.d. from three independent experiments; more than 1000 cells were counted in each individual group. **P<0.01, ***P<0.001.